Instructions for Klacid (Clarithromycin) for suspension preparation
English product name
Klacid®
Release Form
granules d/ingestion 125 mg/5 ml: fl. 42.3 g or 70.7 g combined with dosage spoon or syringe
granules d/prep. must. d/ingestion 250 mg/5 ml: fl. 49.5 g or 70.7 g combined with dosage spoon or syringe
Description
Granules for preparing a suspension for ingestion in the form of a granulated powder in a white to light yellow colour, with a fruity aroma; when shaken with water, an opaque suspension in a white to light yellow colour is formed, with a fruity aroma.
5 ml ready-made susp.
clarithromycin 250 mg
Auxiliary substances: carbomer (carbopole 974P) - 150 mg, povidon K90 - 35 mg, silicon dioxide - 10 mg, maltodextrin - 238.1 mg, sucrose - 2276.2 mg, titanium dioxide - 35.7 mg, xanthane gum - 3.8 mg, fruity flavoring - 35.7 mg, potassium sorbat - 20 mg, citric acid - 4.24 mg, hypromellose phthalate - 304.2 mg, castor oil - 32.1 mg.
49.5 g - plastic bottles with a volume of 70 ml (1), complete with a dosing spoon or a dosing syringe - cardboard packs.
70.7 g - plastic bottles with a volume of 100 ml (1), complete with a dosing spoon or a dosing syringe - cardboard packs.
ATC codes
J01FA09 Clarithromycin
Clinical-pharmacological groups / Group affiliation
Macrolide group antibiotic
Active substance
clarithromycin
Pharmaco-therapeutic group
Antibiotic, macrolide
Storage Conditions
The drug should be stored in a place inaccessible to children, protected from light at a temperature not higher than 30 ° C.
Best before date
The shelf life is two years. Do not apply after the expiry date indicated on the package.
The finished suspension should be stored at a temperature of 15° to 30°C. The shelf life of the finished suspension is 14 days.
Pharmacological effect Klacid
A semi-synthetic antibiotic of the macrolide group. It has an antibacterial effect by interacting with the 50S ribosomal subunit of bacteria and inhibiting the synthesis of protein-sensitive bacteria.
Testimony Klacid
- Infectious inflammatory diseases caused by clarithromycin-sensitive microorganisms:
- lower respiratory tract infections (such as bronchitis, pneumonia);
- upper respiratory tract infections (such as pharyngitis, sinusitis);
- Skin and soft tissue infections (such as folliculitis, subcutaneous inflammation, and horn);
- disseminated or localized mycobacterial infections caused by Mycobacterium avium and Mycobacterium intracellulare;
- localized infections caused by Mycobacterium chelonae, Mycobacterium fortuitum, and Mycobacterium kansasii;
- acute otitis mediae.
Method of use, course and dosage Klacid
To be taken inside. The finished suspension should be taken inside regardless of the food intake (including milk).
In order to produce the suspension, water is gradually added to the bottle to a mark (60, 70 or 100 ml) and shaken. The finished suspension can be stored for fourteen days at room temperature (15° to 30°C). Before each application, the suspension should be chatted well.
- Nosology Klacid (ICD codes)
- A31.9
- Infection caused by Mycobacterium, unspecified
- A46
- Rozha
- A48.1
- Legionnaires' disease
- H66
- Pus and unspecified mean otitis
- J01
- Acute sinusitis
- J02
- Acute pharyngitis
- J03
- Acute tonsillitis
- J04
- Acute laryngitis and tracheitis
- J15
- Bacterial pneumonia not classified elsewhere
- J15.7
- Pneumonia caused by Mycoplasma pneumoniae
- J16.0
- Chlamydia-induced pneumonia
- J20
- Acute bronchitis
- J31.2
- Chronic pharyngitis
- J32
- Chronic sinusitis
- J35.0
- Chronic tonsillitis
- J37
- Chronic laryngitis and laryngotracheitis
- J42
- Chronic bronchitis unspecified
- L01
- Impetigo
- L02
- Skin abscess, boils and carbuncles
- L03
- Phlegmona
- L08.0
- Piodermia
- L08.8
- Other Refined Local Skin and Subcutaneous Fibre Infections
- L73.9
- Hair follicle disease unspecified
- T79.3
- Post-traumatic wound infection not classified elsewhere